Safety of antipsychotics in people with intellectual disability
Authors:
- Valeria FrighiVFValeria Frighi
- Matthew T. StephensonMSMatthew T. Stephenson
- Alireza MorovatAMAlireza Morovat
- Iain E. JolleyIJIain E. Jolley
- Marialena TrivellaMTMarialena Trivella
- Christina A. DudleyCDChristina A. Dudley
- Ezhil AnandEAEzhil Anand
- Sarah J. WhiteSWSarah J. White
- Christina V. HammondCHChristina V. Hammond
- Rena A. HockneyRHRena A. Hockney
- Beryl BarrowBBBeryl Barrow
- Rehana ShakirRSRehana Shakir
- 1 October 2011
- journal article
- research article
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 199 (4) , 289-295
Abstract
Background: Despite frequent use, little is known about the metabolic and endocrine side-effects of antipsychotics in individuals with intellectual disability.Aims: To compare indices of obesity, glucose, lipids and prolactin between antipsychotic-treated and antipsychotic-naive individuals with intellectual disability and also between participants with intellectual disability and controls from the general population.Method: Observational study comparing 138 antipsychotic-treated and 64 antipsychotic-naive participants with intellectual disability in one National Health Service trust with general population controls.Results: Antipsychotic treatment comprised: risperidone 48%, olanzapine 18%, thioxanthenes 10%, other 24%; monotherapy 95% of participants; mean treatment duration 8 years; median daily chlorpromazine equivalent dose 108mg (range 16–667). Metabolic indices were the same or more favourable in the intellectual disability group than the general population control group but overweight/obesity and type 2 diabetes were more prevalent in the women in the intellectual disability group than the control group. Metabolic indices were similar, statistically or clinically, between the antipsychotic-treated and the antipsychotic-naive groups but there was a non-significant trend towards a higher rate of type 2 diabetes in the antipsychotic group. A total of 100% and 70% of participants on amisulpride/sulpiride and risperidone respectively had hyperprolactinaemia, with secondary hypogonadism in 77% and 4% of affected women and men.Conclusions: Antipsychotics, on average, did not increase metabolic risk, although the existence of a susceptible subgroup at risk of diabetes cannot be excluded. Some antipsychotics induced hyperprolactinaemic hypogonadism, requiring active management. However, our findings suggest that antipsychotics at the low doses routinely prescribed for people with intellectual disability are generally safe in relation to metabolic adverse effects, even if efficacy remains poorly defined.Keywords
This publication has 32 references indexed in Scilit:
- Endocrine and musculoskeletal abnormalities in patients with Down syndromeNature Reviews Endocrinology, 2009
- Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophreniaJournal of Psychopharmacology, 2008
- Vitamin D and fractures in people with intellectual disabilityJournal of Intellectual Disability Research, 2006
- Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES IIISchizophrenia Research, 2005
- Risperidone-Induced Prolactin Elevation in a Prospective Study of Children, Adolescents, and Adults with Mental Retardation and Pervasive Developmental DisordersJournal of Child and Adolescent Psychopharmacology, 2005
- Underweight, obesity and exercise among adults with intellectual disabilities in supported accommodation in Northern EnglandJournal of Intellectual Disability Research, 2004
- Psychotropic medication in adults with mental retardation: prevalence, and prescription practicesResearch in Developmental Disabilities, 2004
- The use of anti‐psychotic drugs with adults with learning disabilities and challenging behaviourJournal of Intellectual Disability Research, 1995
- A STUDY OF SERUM PROLACTIN LEVELS IN SCHIZOPHRENIA: COMPARISON OF MALES AND FEMALESClinical and Experimental Pharmacology and Physiology, 1992
- Decreased Bone Density in Hyperprolactinemic WomenNew England Journal of Medicine, 1980